Collaboration enables the clinical development of niraparib in China by Zai Lab TESARO retains right to co-market in China and receives option to license up to two novel immuno-oncology programs outside ...
- TheStreet.com•7 days ago
Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.
- Investor's Business Daily•9 days ago
Biotech M&As could be heating up, with firms that are developing some potential major drugs attracting interest, says RBC.
Tesaro, Inc. (TSRO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||98.01 x 400|
|Ask||98.18 x 100|
|Day's Range||96.56 - 101.34|
|52wk Range||29.51 - 110.48|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-14.06|
|Avg Vol (3m)||1,201,295|
|Dividend & Yield||N/A (N/A)|